PTP1B and PTPN2 Inhibitors for T Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preparing cells for adoptive cell transfer in cancer immunotherapy are suboptimal, resulting in reduced cell killing capacity of target cells, such as tumor cells, and there is a need for improved methods to stimulate the immune system for cancer treatment.
Innovation Solution
Inhibiting PTP1B and PTPN2 in leukocytes, particularly T cells, using specific inhibitors to enhance their cytotoxic capabilities, allowing for the expansion and modification of cells to increase their antigen-specific cytotoxic properties and persistence.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current methods are used to prepare cells for adoptive cell transfer, then the cell preparation process is simple, but the cell killing capacity against target cells is reduced
Solution Approach 1:
The patent changes the biochemical parameters of T cells by inhibiting PTP1B and PTPN2 phosphatases using specific inhibitors (e.g., trodusquemine for PTP1B and aristolochic acid for PTPN2). This parameter change enhances T cell activation, proliferation, and cytotoxicity without fundamentally altering the cell preparation workflow, thereby improving cell killing capacity while maintaining relative simplicity
2Reliability
If T cells are cultured under conventional conditions, then the culture process is straightforward, but the essential functions of T cells such as antigen specific cytotoxic activity are impaired
Solution Approach 1:
The patent enables T cells to self-enhance their functional capabilities by inhibiting endogenous phosphatases PTP1B and PTPN2 that normally dampen T cell receptor signaling. The inhibitors cause T cells to automatically improve their own activation, proliferation, and cytotoxic functions without requiring external modification or complex culture conditions, maintaining ease of manufacture
3Reliability
If PTP1B and PTPN2 are inhibited in leukocytes, then the cytotoxic capacity and persistence of T cells is enhanced, but the complexity of the treatment protocol increases
Solution Approach 1:
The patent applies PTP1B and PTPN2 inhibition during the ex vivo expansion phase of T cell preparation, before the cells are infused into the patient. This preliminary action ensures that the T cells are pre-activated and optimized for cytotoxic function before encountering the tumor, enhancing treatment effectiveness while avoiding the need for complex post-infusion pharmacological interventions
Data Source
AI summary
The present invention generally relates to methods of activating cells via the inhibition of PTP1B and PTPN2 for use in therapy. For example, the invention relates to preparing cells ex vivo for use in immunotherapy, particularly cancer immunotherapy. More specifically, the invention relates to methods for the preparation of leukocytes, particularly T cells, exhibiting cytotoxic properties for use in adoptive cell transfer. The invention also relates to cells and compositions including them for cancer immunotherapy. The invention also relates to methods of immunotherapy, particularly cancer immunotherapy.